News
3h
Que.com on MSNAI in FDA Drug Approvals Sparks Controversy Over Fabricated StudiesIn recent years, Artificial Intelligence (AI) has made significant strides across various sectors, providing innovative solutions and enhancing efficiency. However, ...
Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...
Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...
Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.
The US Food and Drug Administration appears poised to continue with a plan to ban prescription fluoride supplements at a time ...
The mind-expanding drugs may help heal many mental health conditions. But studies haven’t actually proved that yet.
In a complete response letter, the FDA indicates the drug trial is not an adequate, well-controlled clinical investigation, ...
The FDA's generative AI, Elsa, has a massive hallucination problem, according to the agency's employees themselves.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results